TUBB
ENSG00000196230
Target class
Structural protein
Chromosome
6
Approved drugs
19
Clinical candidates (approved and in development)
84
- Approved drugs
- 19
- Clinical candidates (approved and in development)
- 84
- Chemical probe available
- Yes
- Target name
- TUBB
- Gene name
- Tubulin beta class I
- Gene symbol
- TUBB
- Protein name
- Tubulin beta chain (Tubulin beta-5 chain)
- OK/SW-cl.56
- MGC16435
- M40
- Tubb5
- Gene biotype
- Protein coding
- Gene family
- Tubulin beta family
- Target class
- Structural protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 1,285.7
- Tissue specificity (Gini)
- 0.35
- Tissue specificity (tau)
- 0.831
- KEGG gene identifiers
- hsa:203068
- Protein interaction confidence
- 0.843289
- Protein interaction partners
- 97
- R-HSA-2565942
- R-HSA-380259
- R-HSA-380270
- R-HSA-380284
- R-HSA-380320
- R-HSA-5620912
- R-HSA-6798695
- R-HSA-8854518
- R-HSA-9679191
- End position
- 30725538
- Start position
- 30717435
- Chromosome
- 6
- Strand
- Forward
- Cytoplasm, cytoskeleton .
- Basal body
- Cytokinetic bridge
- End piece
- Flagellar centriole
- Microtubules
- Mitotic spindle
- Primary cilium
- Primary cilium tip
- Principal piece
Publication evidence
- PubMed 26637975
- Tissue specificity (tau)
- 0.830946
- Expression inequality (Gini)
- 0.350142
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 1,285.7
- Cells - Cultured fibroblasts
- 891.79
- Ovary
- 555.65
- Uterus
- 414.56
- Cervix - Endocervix
- 370.61
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes1,285.7
- Cells - Cultured fibroblasts891.79
- Ovary555.65
- Uterus414.56
- Cervix - Endocervix370.61
- Cervix - Ectocervix355.06
- Artery - Aorta332.46
- Nerve - Tibial312.5
- Colon - Sigmoid311.71
- Fallopian Tube311.55
- Artery - Coronary299.73
- Vagina294.35
- Adipose - Subcutaneous289.58
- Artery - Tibial278.21
- Lung276.6
- Esophagus - Muscularis269.52
- Esophagus - Gastroesophageal Junction261.37
- Brain - Cerebellar Hemisphere249.48
- Adipose - Visceral (Omentum)248.31
- Esophagus - Mucosa243.06
- Bladder238.33
- Spleen231.84
- Breast - Mammary Tissue224.84
- Colon - Transverse215.29
- Brain - Hypothalamus210.73
And 29 more, listed on the interactive page.
- GO:0007017
- GO:0030705
- GO:0051301
- GO:0071895
- GO:0005576
- GO:0005634
- GO:0005641
- GO:0005737
- GO:0005829
- GO:0005856
- GO:0005874
- GO:0005929
- GO:0015630
- GO:0035578
- GO:0036464
- GO:0044297
- GO:0045171
- GO:0070062
- GO:0072686
- GO:0097228
- GO:0097229
- GO:0097542
- GO:0005198
- GO:0005515
- GO:0031625
- GO:0042288
Related records
Trials (9,123)
- 'ADVANCE' (A Pilot Trial)
- "Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer
- "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"
- "Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"
- [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
- [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
- 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer
- 1 or 6 Months of Dual Antiplatelet Therapy After Drug-coated Balloon Angioplasty for De-novo Small Coronary Artery Disease
- 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
- 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)
- 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
- 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
- 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
- 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
- 1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
- 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)
- 3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
Drugs (89)
- ABT-751 Tubulin beta inhibitor
- AGS-16C3F Tubulin disrupting agent
- Anetumab ravtansine Tubulin inhibitor
- ANG1005 Tubulin inhibitor
- Anvatabart opadotin Tubulin inhibitor
- Aprutumab ixadotin Tubulin inhibitor
- ASG-5ME Tubulin inhibitor
- AVE-9633 Tubulin inhibitor
- Azintuxizumab vedotin Tubulin inhibitor
- Belantamab mafodotin Tubulin inhibitor
- BIIB-015 Tubulin inhibitor
- Bivatuzumab mertansine Tubulin inhibitor
- BMS-275183 Tubulin stabiliser
- Brentuximab vedotin Tubulin inhibitor
- Cabazitaxel Tubulin inhibitor
- Cantuzumab mertansine Tubulin inhibitor
- Cantuzumab ravtansine Tubulin inhibitor
- Colchicine Tubulin inhibitor
- Coltuximab ravtansine Tubulin inhibitor
- Crolibulin Tubulin inhibitor